Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for PIK3CA-Related Overgrowth
NCT02443818Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- May 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in PIK3CA-related overgrowth spectrum (PROS), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Measure of the relative percentage of the excess tissue volume evolution at the affected site by volumetric MRI at 12 months. Started May 2015; status: completed.
02
Drugs
sirolimus
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on NCT02443818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02443818.